COMP <GO>
SYK vs ABBV // ALTMAN Z-SCORE & DEBT/EQUITY
Stryker Corporation (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: SYK 7
— ABBV 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: ABBV
LAST: $291.86 (-6.38%) • MKT CAP: $119.58B
balance-sheet
4.46
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
balance-sheet
5.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SYK VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SYK | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.00% | 70.20% | -6.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.60% | 29.00% | -17.40 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 23.6x | 33.3x | -9.70 | SYK | /valuation <GO> |
| Free Cash Flow Yield | 3.58% | 3.47% | +0.11 | SYK | /fcf-yield <GO> |
| Operating Margin | 19.50% | 24.60% | -5.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 12.90% | 6.90% | +6.00 | SYK | /net-margins <GO> |
| Revenue Growth (YoY) | 11.20% | 8.60% | +2.60 | SYK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.07% | 2.27% | -1.20 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 4.46 | 5.33 | -0.87 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | SYK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 7.40% | -0.10 | SYK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.0 | 72.8 | -24.80 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.13 | 1.15 | -0.02 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.2x | 113.1x | -78.90 | SYK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $119.58B | $513.86B | -$394.28B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SYK REV | ABBV REV | SYK GROSS % | ABBV GROSS % | SYK FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $25.12B | $61.16B | 64.0% | 70.2% | $4.28B | $17.82B |
| FY 2024 | $22.59B | $56.33B | 63.9% | 70.0% | $3.49B | $17.83B |
| FY 2023 | $20.50B | $54.32B | 44.0% | 44.0% | $2.79B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SYK // BETA 1.13
ABBV // BETA 1.15